Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial

Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial

Residual androgen production causes tumor progression in metastatic, castration-resistant prostate cancer (mCRPC) patients. Abiraterone acetate (AA), a prodrug of abiraterone, is an oral CYP-17 inhibitor that blocks androgen production. It was hypothesized that adherence-enhancing measures (AEM) mig...

Full description

Bibliographic Details
Main Authors: Henrik Suttmann, Jochen Gleissner, Andreas Huebner, Tim Mathes, Werner Baurecht, Katrin Krützfeldt, Hussein Sweiti, Susan Feyerabend
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Cancers
Subjects:
metastatic castration-resistant prostate cancer
abiraterone acetate
adherence
discontinuation
MMAS-4
quality of life
Online Access:https://www.mdpi.com/2072-6694/12/9/2550

Similar Items

Similar Items